Verano Holdings (VRNO) Cash from Financing Activities (2021 - 2026)
Verano Holdings' (VRNO) quarterly Cash from Financing Activities came in at -$12.4 million in Q1 2026, down 1994.42% year-on-year from $653393.9 in Q1 2025, and down 230.61% on a QoQ basis from -$3.7 million in Q4 2025.
Verano Holdings (VRNO) Cash from Financing Activities (2021 - 2026) Analysis & Trends
Verano Holdings (VRNO) has 6 years of Cash from Financing Activities data on file, last reported at -$12.4 million in Q1 2026.
- On a quarterly basis, Cash from Financing Activities fell 1994.42% year-over-year to -$12.4 million in Q1 2026; TTM through Mar 2026 was -$37.1 million, a 42.2% increase from a year earlier, with the FY2025 full-year figure at -$25.3 million, up 61.59% from the prior year.
- Cash from Financing Activities for Q1 2026 stood at -$12.4 million, down from -$3.7 million in the prior quarter.
- Over the last five years, Cash from Financing Activities for VRNO reached as high as $92.8 million in Q1 2022 and fell as low as -$53.2 million in Q2 2024.
- Historically, Cash from Financing Activities has averaged $586705.9 across 5 years, with a median of -$2.3 million in 2024.
- Across the five-year window, Cash from Financing Activities soared 975.57% in 2023 and plunged 1994.42% in 2026, its largest moves.
- Year by year, Cash from Financing Activities stood at $2.1 million in 2022, then surged by 975.57% to $22.3 million in 2023, then sank by 137.15% to -$8.3 million in 2024, then surged by 54.84% to -$3.7 million in 2025, then sank by 230.61% to -$12.4 million in 2026.
- Per Business Quant data, the three most recent Cash from Financing Activities figures were -$12.4 million in Q1 2026, -$3.7 million in Q4 2025, and -$4.8 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 13.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | -840.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -494.13 Mn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | -1.48 Bn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | -203.80 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | -86.10 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | -65.00 Mn |
| 10 | Verano Holdings | 2.02 Bn | 1.94 Bn | 98.98 Mn | -12.38 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -12.38 Mn |
| Mar 31, 2026 | -12.38 Mn |
| Dec 31, 2025 | -3.74 Mn |
| Dec 31, 2025 | -3.74 Mn |
| Sep 30, 2025 | -4.85 Mn |
| Sep 30, 2025 | -4.85 Mn |
| Jun 30, 2025 | -16.14 Mn |
| Jun 30, 2025 | -16.14 Mn |
| Mar 31, 2025 | -591,000.00 |
| Mar 31, 2025 | -591,000.00 |
| Dec 31, 2024 | -8.29 Mn |
| Dec 31, 2024 | -8.29 Mn |
| Sep 30, 2024 | -2.17 Mn |
| Sep 30, 2024 | -2.17 Mn |
| Jun 30, 2024 | -53.15 Mn |
| Jun 30, 2024 | -53.15 Mn |
| Mar 31, 2024 | -2.32 Mn |
| Mar 31, 2024 | -2.32 Mn |
| Dec 31, 2023 | 22.32 Mn |
| Dec 31, 2023 | 22.32 Mn |